×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Vouchers
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Moneycontrol mutual fund summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Budget 2026
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
PF
Forum
Videos
you are here:
Home
News
Drl
Drl
Dr Reddy’s: Acceleration in EM opportunity to help re-rate company
Ideas for profit | Dr Reddy’s: COVID opportunity key growth lever
In a major win for Dr Reddy’s, US court allows sale of generic Suboxone film
Dr Reddy’s plummets 23% as Jefferies red flags ‘repeat’ observations
Pharma: Here's what all happened in the sector last week
DRL says no claims for monetary damages in US patent case
Good Q3 but Dr Reddy's still far from sustainable growth: Expert
See Nuvaring opportunity for Dr Reddy's in Q4FY18: Credit Suisse
New guidelines to cut approval time of biosimilars in half
Sensex, Nifty under pressure; Dr Reddy's jumps 3%, SBI falls
Dr Reddy's ink pact with Purdue varsity for drug research
Accumulate Dr Reddys Labs; target of Rs 3957: KRChoksey
Buy Dr Reddys Laboratories; target of Rs 3878: Angel
Dr Reddy's launches antibiotic drug in US market
Mkt will keep eye on RBI commentary on inflation: Religare
Buy Dr Reddys Laboratories, says Sukhani
BSE Sensex gains; tech drags, Cipla & DRL up over 2%
Nifty flirts with 6000; DRL falls 2.1%, Eicher up 6.9%
Nifty stuck at 6000; oil stocks rally, Aptech surges 9%
Dr Reddy's Lab appoints GV Prasad as chairman
Anji Reddy passes away
Hold Dr Reddys Laboratories: Ventura Securities
DRL gains for sixth day, Morgan Stanley says overweight
Stocks in news: Chettinad Cement, GMR, Suzlon, DRL
Bristol-Myers sues DRL for patent infringement in US
View More
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio